Download PDF

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: June 15th, 2012 - June 15th, 2013

Target Audience

This activity was developed for physicians, pharmacists, nurses, and other healthcare professionals.

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Describe the impact of recent advances and emerging therapies in the treatment of patients with CINV
  • Compare key recommendations from updated clinical practice guidelines for the management of CINV, including those established by ASCO, NCCN, MASCC, and ONS
  • Examine value-based treatment strategies for preventing and improving outcomes in patients with CINV

Physician Credit Designation

The Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical Learning Institute, Inc. and the Center of Excellence Media, LLC. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.25 contact hours.

Registered Pharmacy Designation

Medical Learning Institute (MLI) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-12-016-H01-P.


Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Planners’ and Managers’ Disclosures

Shelley Chun, PharmD, MLI Reviewer, has nothing to disclose.
Loretta M. Fala, medical writer, has nothing to disclose.
Ryan Sims, CRNA, MS, MLI Reviewer, has nothing to disclose.
William J. Wong, MD, MLI Reviewer, has nothing to disclose.

Faculty Disclosures

Steven M. Grunberg, MD, is a consultant to AP Pharma, Archimedes Pharma, Helsinn, Merck, and Tesaro, and is on the speaker’s bureau for and has stock in Merck.
Atheer A. Kaddis, PharmD, has nothing to disclose.
James J. Natale, PharmD, BCOP, is on the speaker’s bureau for Eisai and Merck.
Kimberly Noonan, MS, RN, ANP, AOCN, has nothing to disclose.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity for any amount during the past 12 months.


The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias toward or promotion for any agent discussed in this program should be inferred.

Estimated time to complete activity: 1.25 hours
Date of original release: June 15, 2012
Valid for CME/CE credit through: June 15, 2013

Related Items
Emerging Treatments and Evolving Strategies for the Cost Effective Management of Multiple Myeloma
Jonathan L. Kaufman, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Emerging Treatments and Evolving Strategies for the Cost-Effective Management of Myelofibrosis
Gary M. Owens, MD, Alfonso Quintas-Cardama, MD , Atheer A. Kaddis, PharmD
Interactive Learning published on July 15, 2012
Advances in Treatment Options and Management of Chemotherapy-induced Nausea and Vomiting
Steven M. Grunberg, MD, Lisa Lohr, PharmD, BCPS, BCOP, Jennifer Webster, MN, RN, AOCN
Supplements published on March 31, 2010
Last modified: January 9, 2020